Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07544654 · ClinicalTrials.gov registry record · Phase 3
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Not yet
- Registry status
- Phase 3
- Development phase
- 390
- Enrollment target
NCT07544654 is a Phase 3 study that has not yet begun recruiting, run by Boehringer Ingelheim. The registered enrollment target is 390 participants.
The verdict
NCT07544654, a Phase 3 study, has not yet begun recruiting, sponsored by Boehringer Ingelheim.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 390 participants
- Enrollment target
Study Summary
This study is open to adults with advanced extrapulmonary neuroendocrine cancer. The purpose of this study is to find out if a study medicine called obrixtamig plus standard chemotherapy (carboplatin and etoposide) improves survival when compared to standard chemotherapy (carboplatin and etoposide) alone. Obrixtamig is an antibody-like molecule that may help the immune system fight cancer. Another purpose of the study is to test a medical device being developed to measure levels of the tumour marker delta-like ligand 3 (DLL3). Participants are put into 2 groups randomly, which means by chance. One group (treatment arm) receives obrixtamig and standard chemotherapy followed by obrixtamig alone for up to 3 years. The other group (control arm) receives standard chemotherapy without obrixtamig for about 4 months. All treatments are given as infusions into a vein. During the study, participants in both groups visit the study site regularly. Participants in the treatment arm stay overnight at the study site following the first 2 obrixtamig treatments. The doctors regularly check participants' health and take note of any unwanted effects. At some of the visits, doctors check the size of the tumour(s). The results are compared between the 2 groups to see whether the treatment works.
Interventions
- DRUG Carboplatin
- DRUG Etoposide
- DRUG Obrixtamig
- DEVICE Ventana DLL3 RxDx assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 390 participants |
| Start Date | 2026-07-07 |
| Est. Completion | 2031-03-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07544654
The ClinicalTrials.gov registry entry for NCT07544654 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 390 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT07544654 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07544654 about?
NCT07544654 is a clinical study titled "DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy". This study is open to adults with advanced extrapulmonary neuroendocrine cancer. The purpose of this study is to find out if a study medicine called obrixtamig plus standard chemotherapy (carboplatin and etoposide) improves survival when compared to standard chemotherapy (carboplatin and etoposide) ...
What is the current status of trial NCT07544654?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 390 participants. The study started on 2026-07-07. Estimated completion is 2031-03-11.
What interventions are being tested in trial NCT07544654?
The interventions under investigation include: Carboplatin (DRUG), Etoposide (DRUG), Obrixtamig (DRUG), Ventana DLL3 RxDx assay (DEVICE).
Who is sponsoring clinical trial NCT07544654?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.